CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flow from operating activities
Net loss	$ (8,583)	$ (7,023)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	161	160
Depreciation	265	251
Stock-based compensation	554	793
Impairment of technology license	608	0
Change in fair value of warrant liability	0	(2,374)
Loss on extinguishment of warrant liability	0	440
(Increase) decrease in assets
Prepaid drug product for testing	785	(741)
Other current assets	(240)	549
Increase (decrease) in liabilities
Accounts payable and accrued expenses	326	(12)
Net cash used in operating activities	(6,124)	(7,957)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(17)	(538)
Net cash used in investing activities	(17)	(538)
Cash flow from financing activities
Net proceeds from sale of common stock	1,180	3,567
Net proceeds from exercise of warrants	0	1,518
Net cash provided by financing activities	1,180	5,085
Net decrease in cash	(4,961)	(3,410)
Cash, beginning of period	5,965	9,375
Cash, end of period	1,004	5,965
Non-cash financing activities
Warrants transferred to equity upon modification	0	797
Conversion of warrant liability to equity	$ 0	$ 175